Study Summary
This trial is testing a new drug, UX701, to see if it is safe for people with Wilson Disease and if it helps regulate copper levels.
- Wilson's Disease
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
19 Primary · 6 Secondary · Reporting Duration: Up to Week 312
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
12 Treatment Groups
Stage 2: UX701 or Placebo
1 of 12
Stage 1: UX701 Dose Level 2
1 of 12
Stage 2: UX701
1 of 12
Stage 3: UX701
1 of 12
Stage 1: UX701 Dose Level 3
1 of 12
Stage 1: UX701 Dose Level 1
1 of 12
Stage 3: Placebo or UX701
1 of 12
Stage 1: Placebo Dose Level 2
1 of 12
Stage 3: Placebo
1 of 12
Stage 1: Placebo Dose Level 3
1 of 12
Stage 1: Placebo for Dose Level 1
1 of 12
Stage 2: Placebo
1 of 12
Experimental Treatment
Non-Treatment Group
78 Total Participants · 12 Treatment Groups
Primary Treatment: oral corticosteroids · Has Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What are the prominent conditions that UX701 is utilized to address?
"UX701 is often used to manage allergic contact dermatitis, but its efficacy also extends to treating nephrotic syndrome, vasculitis, and synovitis." - Anonymous Online Contributor
What is the current scope of this trial's presence in clinics?
"This medical experiment is being conducted at Indiana University in Indianapolis, the University of Miami in Florida, and UCLA in California. Additionally, there are 10 other sites participating as well." - Anonymous Online Contributor
How many participants are in this clinical trial?
"Affirmative. Clinicaltrials.gov's data reveals that this study, first posted on September 27th 2021 is currently recruiting participants. Approximately 78 volunteers must be registered from 10 clinical sites." - Anonymous Online Contributor
Has there been previous research examining UX701?
"UX701 was initially investigated by Karolinska Institutet in 2002, with a total of 18518 trials completed to date. There are 87 clinical experiments presently taking place, predominantly centered around Indianapolis, Indiana." - Anonymous Online Contributor
Are there any vacancies within this clinical investigation?
"As confirmed on clinicaltrials.gov, this trial is currently seeking participants and has been since it was published on September 27th 2021 with the most recent update being issued November 2nd 2022." - Anonymous Online Contributor